Document is current
Any future updates will be listed below
-
Authors
Liu, Zezhong
Chan, Jasper Fuk-Woo
Zhou, Jie
Wang, Meiyu
Wang, Qian
Zhang, Guangxu
Xu, Wei
Chik, Kenn Ka-Heng
Zhang, Yilong
Wang, Youchun http://orcid.org/0000-0001-9769-5141
Yuen, Kwok-Yung http://orcid.org/0000-0002-2083-1552
Lu, Lu http://orcid.org/0000-0002-2255-0391
Jiang, Shibo http://orcid.org/0000-0001-8283-7135
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (92169112, 82041036)
China Postdoctoral Science Foundation (2021M700840)
- License Information
-
More Information
Article History
Received: 9 January 2022
Accepted: 5 February 2022
First Online: 24 February 2022
Competing interests
: L.L., S.J., Z.L, J.Z., W.X., Q.W. and Y.Z. filed a patent application for the STING agonist of CF501. J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. Other authors declare that they have no competing interests.
Free to read: This content has been made available to all.
